PMID- 32822687
OWN - NLM
STAT- MEDLINE
DCOM- 20220203
LR  - 20220203
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
VI  - 145
DP  - 2020 Nov
TI  - Mirabegron Versus Solifenacin in Multiple Sclerosis Patients With Overactive 
      Bladder Symptoms: A Prospective Comparative Nonrandomized Study.
PG  - 94-99
LID - S0090-4295(20)30994-8 [pii]
LID - 10.1016/j.urology.2020.08.008 [doi]
AB  - OBJECTIVE: To determine the patient-perceived effectiveness and tolerability of 
      mirabegron compared to solifenacin in a multiple sclerosis (MS) population with 
      overactive bladder (OAB) symptoms. MATERIALS AND METHODS: MS patients with OAB 
      symptoms who were not on medication for their urinary symptoms at enrollment were 
      prospectively recruited. Patients enrolled in years 1-2 were prescribed 
      mirabegron, whereas patients enrolled in years 3-4 were prescribed solifenacin. 
      At enrollment and 6-week follow-up, patients completed several patient reported 
      outcome measures. The primary outcome was change in OAB Questionnaire Short Form 
      (OAB-q SF) symptom severity and minimal clinically important difference (MCID) 
      achievement. The Patient Assessment of Constipation Symptoms (PAC-SYM) was used 
      to assess bowel function over the treatment period. RESULTS: Sixty-one patients 
      were enrolled. The majority of the mirabegron (70%) and the solifenacin (69%) 
      group achieved the OAB-q SF symptom severity MCID. The solifenacin group had a 
      statistically significant greater decrease in its end of study OAB-q SF score 
      (Delta = -37.87 vs -20.43, P = .02). Constipation improved in the mirabegron group 
      and worsened in the solifenacin group (DeltaPAC-SYM = -0.38 vs +0.22; P = .02), with 
      30% of patients prescribed solifenacin experiencing worsening above the MCID 
      threshold. CONCLUSION: Among MS patients, we demonstrated similar response rates 
      to mirabegron and solifenacin, with approximately 50%-70% achieving each patient 
      reported outcome measure's MCID. Though this small study showed some short-term 
      evidence that improvement in urinary symptom severity was greater with 
      solifenacin, this potential benefit must be weighed against the observed risk of 
      worsening constipation. Further studies are needed to confirm these findings.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Brucker, Benjamin M
AU  - Brucker BM
AD  - New York University Langone Health, New York, NY. Electronic address: 
      Benjamin.Brucker@nyulangone.org.
FAU - Jericevic, Dora
AU  - Jericevic D
AD  - New York University Langone Health, New York, NY.
FAU - Rude, Temitope
AU  - Rude T
AD  - University of Southern California, Los Angeles, CA.
FAU - Enemchukwu, Ekene
AU  - Enemchukwu E
AD  - Stanford University, Stanford, CA.
FAU - Pape, Dominique
AU  - Pape D
AD  - New York University Langone Health, New York, NY.
FAU - Rosenblum, Nirit
AU  - Rosenblum N
AD  - New York University Langone Health, New York, NY.
FAU - Charlson, Erik R
AU  - Charlson ER
AD  - New York University Langone Health, New York, NY.
FAU - Zhovtis-Ryerson, Lana
AU  - Zhovtis-Ryerson L
AD  - New York University Langone Health, New York, NY.
FAU - Howard, Jonathan
AU  - Howard J
AD  - New York University Langone Health, New York, NY.
FAU - Krupp, Lauren
AU  - Krupp L
AD  - New York University Langone Health, New York, NY.
FAU - Peyronnet, Benoit
AU  - Peyronnet B
AD  - New York University Langone Health, New York, NY.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
DEP - 20200819
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (Acetanilides)
RN  - 0 (Thiazoles)
RN  - 0 (Urological Agents)
RN  - KKA5DLD701 (Solifenacin Succinate)
RN  - MVR3JL3B2V (mirabegron)
SB  - IM
MH  - Acetanilides/*administration & dosage/adverse effects
MH  - Adult
MH  - Constipation/chemically induced/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis/*complications
MH  - Patient Reported Outcome Measures
MH  - Prospective Studies
MH  - Severity of Illness Index
MH  - Solifenacin Succinate/*administration & dosage/adverse effects
MH  - Thiazoles/*administration & dosage/adverse effects
MH  - Treatment Outcome
MH  - Urinary Bladder, Overactive/diagnosis/*drug therapy/etiology
MH  - Urological Agents/administration & dosage/adverse effects
EDAT- 2020/08/22 06:00
MHDA- 2022/02/04 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/04/25 00:00 [received]
PHST- 2020/08/04 00:00 [revised]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2022/02/04 06:00 [medline]
PHST- 2020/08/22 06:00 [entrez]
AID - S0090-4295(20)30994-8 [pii]
AID - 10.1016/j.urology.2020.08.008 [doi]
PST - ppublish
SO  - Urology. 2020 Nov;145:94-99. doi: 10.1016/j.urology.2020.08.008. Epub 2020 Aug 
      19.